1152 related articles for article (PubMed ID: 9122739)
21. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
22. Topotecan in small cell lung cancer.
Schiller JH
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-27-S20-33. PubMed ID: 9425958
[TBL] [Abstract][Full Text] [Related]
23. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
[TBL] [Abstract][Full Text] [Related]
24. Topotecan in the treatment of non-small cell lung cancer.
Perez-Soler R
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-34-S20-41. PubMed ID: 9425959
[TBL] [Abstract][Full Text] [Related]
25. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy of advanced ovarian cancer.
McGuire WP; Ozols RF
Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
29. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
Thigpen JT
Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
32. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Cabanillas F
Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
34. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
[TBL] [Abstract][Full Text] [Related]
35. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
36. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Herzog TJ
Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
[TBL] [Abstract][Full Text] [Related]
37. Achievements and unmet needs in the management of advanced ovarian cancer.
Guarneri V; Piacentini F; Barbieri E; Conte PF
Gynecol Oncol; 2010 May; 117(2):152-8. PubMed ID: 20056266
[TBL] [Abstract][Full Text] [Related]
38. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Markman M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
[TBL] [Abstract][Full Text] [Related]
39. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
